What is the dose of Calcitriol (Rocatrol) for a 2-year-old child weighing 12kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Dosing Information for Calcitriol (Rocaltrol) in Children

The dosing of Calcitriol (Rocaltrol) for a 2-year-old child weighing 12kg can be considered based on the available evidence:

  • According to the study 1, for patients less than 30 kg, the dose of calcitriol is 3 micrograms per dose, administered twice a week.
  • The study 2 provides information on the initial doses of intravenous calcitriol for pediatric end-stage renal disease patients on hemodialysis, which were 0.5-1.5 microg, but this is for a different administration route and patient population.
  • The study 3 suggests a dose of 40 ng/kg/day calcitriol for X-linked hypophosphatemia, but this is a different condition and dosing regimen.
  • The study 4 mentions calcitriol doses for patients with pseudohypoparathyroidism, with some patients requiring doses ≥ 1.5 mcg/day, but this is also a different condition.

Relevant Dosing Regimen

Based on the study 1, which provides dosing information for children with renal osteodystrophy, the dose for a 2-year-old child weighing 12kg would be:

  • 3 micrograms per dose, administered twice a week, as the child weighs less than 30 kg.

References

Research

Calcitriol oral pulse therapy in children with renal osteodystrophy.

Pediatric nephrology (Berlin, Germany), 1995

Research

The efficacy and safety of different doses of calcitriol combined with neutral phosphate in X-linked hypophosphatemia: a prospective study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.